Restore the Clear Labels Act's Core Provisions Before the Senate Vote

I’m writing today to urge you to oppose the current version of the Clear Labels Act unless the Senate restores its two stripped provisions: the unique facility identifier requirement and the one-year compliance timeline. What's headed to the floor now is a shell of the original bill. The DUNS number requirement was the bill's backbone. Without it, linking a drug label to a specific factory — and to FDA inspection records showing mold, leaks, or contaminated water — becomes nearly impossible. This also makes proving liability difficult in court cases where consumers suffer harm. ProPublica found that addresses alone failed to identify the correct facility in nearly a third of cases, and a single address in India can cover multiple factories. The vague "place of business" language makes this worse, potentially letting manufacturers list a U.S. headquarters instead of the overseas factory where the drug was actually made. I also object to the counter from pharma manufacturers that they need FIVE years to be compliant. That five-year compliance window is indefensible, and might even be dangerous. Former FDA inspector Peter Baker said flatly: "If they wanted to do it in one year, they could." Medications from facilities with documented safety failures have already been linked to thousands of adverse patient reactions. All Senators should demand the original bill's provisions be reinstated — not hand the generic drug industry, which spent over $1 million lobbying on this bill, another five years of delay. Oppose/Vote NO on this useless version of the bill. It’s another attempt to shield industry from accountability. Thank you.